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Abstract Dipeptidyl-peptidase IV (DPPIV/CD26) metabolizes
neuropeptides regulating insulin secretion. We studied the in vitro
steady-state kinetics of DPPIV/CD26-mediated truncation of
vasoactive intestinal peptide (VIP), pituitary adenylyl cyclase-
activating peptide (PACAP27 and PACAP38), gastrin-releasing
peptide (GRP) and neuropeptide Y (NPY). DPPIV/CD26
sequentially cleaves off two dipeptides of VIP, PACAP27,
PACAP38 and GRP. GRP situates between the best DPPIV/
CD26 substrates reported, comparable to NPY. Surprisingly,
the C-terminal extension of PACAP38, distant from the scissile
bond, improves both PACAP38 binding and turnover. There-
fore, residues remote from the scissile bond can modulate
DPPIV/CD26 substrate selectivity as well as residues flanking
it. ß 2001 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The exopeptidase dipeptidyl-peptidase IV/CD26 (DPPIV/
CD26; EC 3.4.14.5) [1] liberates X-Pro and X-Ala dipeptides
from the amino-terminus of peptides. In addition, cleavage
after a penultimate Ser, Gly, Thr, Val and Leu has been
observed [2^5]. DPPIV/CD26 occurs in a soluble form in hu-
man serum and is expressed on the surface of endothelial and
epithelial cells.
DPPIV/CD26 is involved in the regulation of speci¢c pep-
tides that serve as reporters within and between the digestive
and endocrine system [6]. The enzyme rapidly inactivates glu-
cagon-like peptide 1 (GLP-1) and glucose-dependent insulino-
tropic peptide (GIP), both potent stimulators of glucose-in-
duced insulin release [7]. The truncation of glucagon by
DPPIV/CD26 has been demonstrated in vitro and the bene¢t
of degradation-resistant analogs has been shown in a glucose
tolerance bioassay [4,8]. Administration of DPPIV/CD26 in-
hibitors improves glucose tolerance in normal and diabetic
animals [9^11]. DPPIV/CD26 inhibition in GLP-1 receptor
3/3 mice still increases signi¢cantly the glucose clearance
rate [12]. This ¢nding urged us to look for additional
DPPIV/CD26 substrates involved in glucose homeostasis.
DPPIV/CD26 is present in the granules of the glucagon-pro-
ducing K-cells of the endocrine pancreas [13]. It is released
together with glucagon in the interstitial space, where it can
interact with secretory peptides of neighboring cells.
Parasympathetic nerve terminals in pancreatic ganglia and
islets express the neuropeptides vasoactive intestinal peptide
(VIP), pituitary adenylyl cyclase-activating peptide (PACAP)
and gastrin-releasing peptide (GRP). They are released upon
stimulation of the parasympathetic nerves and increase insulin
secretion from the L-cells [14]. VIP, a 28-amino-acid peptide,
and PACAP38, a 38-residue peptide with a C-terminally trun-
cated 27-amino-acid variant (PACAP27), belong to the PA-
CAP/glucagon superfamily [15]. With a penultimate serine
and structural similarity to glucagon, VIP, PACAP27 and
PACAP38 are potential DPPIV/CD26 substrates. Since the
amino-terminal His is important for receptor binding, cleav-
age by DPPIV/CD26 would a¡ect the biological activity
[16,17].
GRP is a 27-amino-acid neuropeptide and member of the
bombesin family of peptide hormones [18]. It stimulates the
secretion of various gastrointestinal hormones [18^20] and is a
regulator of the endocrine and exocrine pancreas [21,22].
Nausch et al. reported the sequential cleavage of two dipep-
tides of GRP by DPPIV/CD26, but no kinetic data were pro-
vided [23].
Neuropeptide Y (NPY), an acclaimed DPPIV/CD26 sub-
strate [24], is widely distributed in the nervous system. This
sympathetic cotransmitter is, aside from its cardiovascular
e¡ects, involved in the regulation of insulin release. DPPIV/
CD26-truncation abolishes the binding of NPY with the pan-
creatic receptor and its vasoconstrictive properties, turning it
into a vascular growth factor and feeding promoter [14,25].
We characterized the DPPIV/CD26-mediated truncation of
VIP, PACAP27, PACAP38 and GRP. The truncation of NPY
was used as a reference.
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2. Materials and methods
2.1. Peptides
VIP and VIP(3^28) were synthesized using a solid-phase synthesizer
model 433A (Applied Biosystems, Foster City, CA, USA). PACAP27,
PACAP38 and GRP were purchased from Bachem (Bubendorf, Swit-
zerland). GRP(3^27) was custom synthesized by Neosystem Labs
(Strasbourg, France), NPY was purchased from Sigma (St. Louis,
MO, USA). The concentration of the peptide stock solutions was
determined spectrophotometrically using O276 of 2900 M31 cm31
(VIP), 4350 M31 cm31 (PACAP27), 5800 M31 cm31 (PACAP38),
6850 M31 cm31 (GRP) and 7250 M31 cm31 (NPY).
2.2. DPPIV/CD26 puri¢cation and enzyme activity
Soluble DPPIV/CD26 was puri¢ed from human seminal plasma as
described [26]. The speci¢c activity was 35 U/mg. Contaminating ami-
nopeptidase activity (measured with Ala-4-methoxy-2-naphthylamide)
was 6 0.1%. Enzymatic activity was determined kinetically at 37‡C
using Gly-Pro-p-nitroanilide (0.5 mM) in 40 mM Tris^HCl bu¡er, pH
8.3, at 405 nm (Spectramax 340 microtiterplate reader, Molecular
Devices, Sunnyvale, CA, USA). One unit of activity is de¢ned as
the amount of enzyme that cleaves 1 Wmole of substrate per minute
under these conditions. Protein concentrations were determined using
Bradford reagent with bovine serum albumin as a standard. The the-
oretical Mr of soluble DPPIV/CD26 is 85 123 per subunit.
2.3. Kinetics of peptide conversion
VIP, PACAP27, PACAP38, GRP and NPY (5 WM) were incubated
with DPPIV/CD26 (25, 250 and 2500 U/l for VIP, PACAP27 and
PACAP38; 0.25, 2.5 and 25 U/l for GRP and NPY) in 50 mM
Tris^HCl bu¡er, pH 7.5, 1 mM EDTA at 37‡C. At certain time
intervals, samples were withdrawn and quenched in 0.1% tri£uoro-
acetic acid. Incubation with bu¡er alone and with equal amounts of
DPPIV/CD26 inactivated by diaryl phosphonate inhibitor, served as
negative controls. The samples were desalted using C18 ZipTips
(Millipore, Bedford, MA, USA) and eluted with 50 or 70% acetoni-
trile/0.1% acetic acid in water. The composition of the mixture was
determined with an Esquire LC Ion Trap mass spectrometer (Bruker,
Bremen, Germany) as described [5].
To determine the steady-state kinetic parameters, di¡erent concen-
trations of peptide (5^250 WM for VIP, 5^120 WM for PACAP27 and
PACAP38, 5^100 WM for GRP and 0.625^80 WM for NPY) were
incubated with DPPIV/CD26 for 5^30 min (10^25% conversion).
The amount of converted substrate was calculated from the relative
abundance of intact and cleaved forms. The average rate of conver-
sion was plotted versus the average substrate concentration of the
chosen time interval according to Segel [27]. The results were directly
¢tted to the Michaelis^Menten equation.
2.4. Competition experiments with chromogenic substrate
When two substrates (S and SP) are converted by the same enzyme
(with normal Michaelis^Menten kinetics), the e¡ect of the presence of
SP on the kinetics of S is:
vi  VmaxS
Km 1 S
0
Km 0
 
 S
with Vmax and Km the maximal rate and Michaelis constant for S and
KmP the Michaelis constant for SP. As substrate S we used Gly-Pro-
pNA (25 WM, Km = 100 WM). KmP was calculated from the initial rate
in the absence and presence of a known concentration of peptide (SP).
3. Results
3.1. Speci¢city of cleavage, interpretation of mass spectra
The speci¢city of the reaction between DPPIV/CD26 and
the peptides was con¢rmed by determining the composition of
the reaction mixture in function of time. The observed molec-
ular mass of intact and truncated forms is shown in Table 1.
Cleavage occurred after the penultimate Pro for NPY and
GRP and after the penultimate Ser for VIP, PACAP27 and
PACAP38. VIP, PACAP27, PACAP38 and GRP were
cleaved a second time, respectively, after Ala, Gly and Pro
on position 4. Truncation was prevented by pre-incubation
of DPPIV/CD26 with a speci¢c irreversible inhibitor. The
mass spectra only provide a relative abundance of the mole-
cules in the sample. In order to quantify the amount of pep-
tide converted at various time points, it was necessary to
establish that the signal was proportional to the concentration
and that this proportionality factor was the same for the in-
tact and truncated molecules. Equal volumes of peptide dilu-
tions, that had been incubated with either an excess of
DPPIV/CD26 or the incubation bu¡er, were mixed, desalted
and the ratio of the truncated over intact form was deter-
mined. In practice, the observed ratio approached the calcu-
lated ratio.
3.2. Kinetics of peptide conversion
The time course of degradation of VIP, PACAP27, PA-
CAP38, GRP and NPY is shown in Figs. 1 and 2. The
C-terminal extension of PACAP38 accelerated the N-terminal
truncation compared to PACAP27. The second truncation
of VIP was, unexpected for cleavage after Ala, slower than
the ¢rst since a large proportion of VIP(3^27) transiently ac-
cumulated. The removal of Asp-Gly of PACAP38(3^38) and
PACAP27(3^27), was another 10^30 times slower than the
cleavage after the VIP(3^27) N-terminal Asp-Ala. GRP was
rapidly truncated by DPPIV/CD26 in two consecutive steps
with little accumulation of the intermediate GRP(3^27) (Fig.
2).
The processing of NPY was also fast. We did not obtain the
high kinetic constants reported before [28]. Our kinetic con-
Fig. 1. Time course of degradation of neuropeptides (5 WM) by
DPPIV/CD26 (25 U/l). Upper panel: VIP; lower panel: PACAP27
(solid lines) and PACAP28 (dotted lines) with intact peptide (closed
circles), peptide-2 (open circles) and peptide-4 (closed squares). The
inset shows the steady-state kinetics of VIP (open circles), PA-
CAP27 (closed circles) and PACAP38 (closed squares) truncation by
DPPIV/CD26.
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stants are approximately four-fold lower due to di¡erences in
(1) speci¢c activity of the enzyme preparations used and (2)
the molecular mass used in the calculations [26,29]. The quan-
ti¢cation of peptide degradation requires calibration, adding
another factor of uncertainty. The truncation of NPY did not
deviate from Michaelis^Menten kinetics (Fig. 2, inset).
The catalytic rate constant (kcat) and the Km (Table 2) were
determined from the concentration dependence of the conver-
sion rate (Figs. 1 and 2). The Km values derived from com-
petition experiments with the chromogenic substrate support
the mass spectrometric results.
4. Discussion
DPPIV/CD26 is involved in the processing of several pep-
tides belonging to the PACAP/glucagon family: glucagon
[4,8], GLP-1 [7], GLP-2 [30], growth hormone-releasing factor
(GRF) [2,3], peptide histidine methionine (PHM) and GIP [7].
The in vivo inactivation of GIP, GLP-1 and GLP-2 by
DPPIV/CD26 has been demonstrated [31^33].
In vivo, bioactive peptides act in the pico- or nanomolar
range [24]. At this low substrate concentration the most im-
portant parameter is the selectivity constant, kcat/Km. For the
¢rst truncation of VIP, we obtained a Km value similar to the
Km of 56 WM published for [S2,A15]GRF(1^29)NH2 [2] and a
kcat identical to the kcat reported for glucagon [8]. Previously,
it has been concluded that DPPIV is unable to cleave VIP in
experimental conditions wherein GLP-1, PHM and GIP are
readily truncated [7]. This is consistent with our results indi-
cating a signi¢cantly lower kcat/Km value for VIP than for
these substrates.
PACAP38 is identical to PACAP27, except for the strongly
positively charged C-terminal extension. When the His1 is
removed, PACAP38(2^38) shows improved receptor binding
and signalling compared to PACAP27(2^27) [16]. Surpris-
ingly, PACAP38 has a higher binding a⁄nity for DPPIV/
CD26 and a higher turnover rate. Thus the C-terminal exten-
sion contributes to the interaction with DPPIV/CD26 and
in£uences the active site conformation during the rate-deter-
mining catalytic step. Therefore, it is di⁄cult to predict the
substrate speci¢city of a peptide exclusively from the amino
acid sequence surrounding the scissile bond [5]. The study of
the processing of GRF-analogs also suggested that DPPIV/
CD26 interacts with substrate residues remote from the scis-
sile bond [2].
The kcat/Km of GRP is signi¢cantly higher than for GLP-1
and GIP, whose active intact peptide levels are regulated by
DPPIV/CD26 in vivo. The truncated GRP(5^27) form has
been isolated from dog intestine [34]. It is possible that
GRP, after sequential cleavage by DPPIV/CD26, is rapidly
degraded by other peptidases to shorter forms [35^37]. The
Table 1
Speci¢city of peptide truncation by DPPIV/CD26
N-terminus Calculated Mr a Measured Mr b
VIP HSDAVF- 3325.8 3323.4 þ 1.7
DAVF- 3101.6 3098.4 þ 1.0
VF- 2915.4 2913.0 þ 1.3
PACAP27 HSDGIF- 3147.7 3147.4 þ 0.2
DGIF- 2923.4 2923.3 þ 0.5
IF- 2751.2 2751.3 þ 0.7
PACAP38 HSDGIF- 4534.2 4534.5 þ 0.2
DGIF- 4310.0 4310.3 þ 0.6
IF- 4137.9 4137.6 þ 0.8
GRP VPLPAG- 2859.4 2857.3 þ 1.0
LPAG- 2663.1 2661.2 þ 1.0
AG- 2452.8 2451.1 þ 0.9
NPY YPSKPD- 4271.7 4271.9 þ 0.4
SKPD- 4011.4 4011.5 þ 0.6
aTheoretical average relative molecular mass of the peptides.
bMeasured average relative molecular mass, the error represents the
standard deviation of at least 20 measurements.
Fig. 2. Time course of degradation of neuropeptides (5 WM) by
DPPIV/CD26 (25 U/l). Upper panel: GRP; lower panel: NPY with
intact peptide (closed circles), peptide-2 (open circles) and peptide-4
(closed squares). The inset shows the steady-state kinetics of NPY
(open squares), GRP (closed circles) and GRP(3^27) (open circles)
truncation by DPPIV/CD26.
Table 2
Steady-state kinetics for peptide truncation by DPPIV/CD26
Km (WM) kcat (s31) kcat/Km (M31 s31)
VIP 59 þ 14 0.74 þ 0.06 12 000 þ 2000
VIP(3^28) ND ND 1700 þ 50c
PACAP27 120 þ 50 0.49 þ 0.13 4200 þ 800
PACAP27 (3^27) ND ND 100 þ 50c
PACAP38 35 þ 9 0.85 þ 0.09 24 000 þ 4000
PACAP38 (3^38) ND ND 150 þ 75c
GRP 6 þ 1 11 þ 1 1.8U106 þ 3U105
14 þ 11a;b
GRP(3^27) 20 þ 2 41 þ 2 2.1U106 þ 1U105
20 þ 1a
NPY 52 þ 8 40 þ 3 7.6U105 þ 5U104
37a
The errors represent the standard error on the ¢t.
aKm value determined from competition experiments.
bThis value likely contains a contribution of GRP(3^27) since the
second cleavage is faster than the ¢rst.
cCalculated from the time course of product formation at a single
substrate concentration assumed to be IKm.
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penultimate Pro of GRP is conserved in evolution but no
function has been attributed to it. During future in vivo stud-
ies of GRP it might be interesting to compare its functional
activities in the presence and absence of DPPIV activity
(DPPIV/CD26-de¢cient animals or in vivo inhibition).
It is clear that this in vitro kinetic study primarily contrib-
utes to the understanding of the DPPIV/CD26 enzymatic ac-
tion and substrate selectivity. Obviously the in vivo half-life of
a peptide depends on many factors, including cleavage by
di¡erent exo- and endo-peptidases, cellular uptake, renal
clearance and hepatic metabolism. VIP is rapidly cleared
from plasma in men. A signi¢cant part of the clearance is
attributable to the liver [38,39]. The local concentration of
DPPIV/CD26 and competition between di¡erent substrates
may greatly in£uence the turnover of a given peptide.
In conclusion, DPPIV/CD26 truncates VIP, PACAP27 and
PACAP38 in two consecutive steps. The kinetic constants are
comparable to those reported for homologous peptides. Fur-
thermore, we found that GRP and GRP(3^27) are excellent
DPPIV/CD26 substrates. The ¢nding that the positive C-ter-
minal extension of PACAP38, remote from the scissile bond,
can in£uence both substrate binding and the catalytic rate
constant has important consequences for the concept of
DPPIV/CD26 substrate speci¢city and catalysis.
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